HER2 targeting agents, such as trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1), have greatly improved clinical outcomes for patients with HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.